NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee B meeting minutes

**Minutes:** Confirmed

**Date and time:** Wednesday 13 July 2022, 09:30am for 10am

**Location:** Hybrid Meeting - 2 Redman Place, London, E20 1JQ Via Zoom

## Attendees

Committee members present

1. Dr Charles Crawley (Chair) Present for all items
2. Baljit Singh (Vice-chair/Chair Topic 1) Present for all items
3. Laura Bojke Present for all items
4. Denise Bryceland Present for items 1 – 4.3.2
5. Professor Iolo Doull Present for all items
6. Dr James Fotheringham Present for all items
7. Professor Nicholas Latimer Present for all items
8. Dr Rhiannon Owen Present for all items
9. Anna Pracz Present for all items
10. Gabriel Rogers  Present for all items
11. Dr Stephen Smith Present for all items
12. Dr Toby Smith Present for items 1 – 6.1.3
13. Professor Nicky Welton Present for all items
14. Nigel Westwood Present for all items
15. Peter Wheatley-Price Present for all items
16. Dr Stuart Williams Present for all items
17. Tony Wootton Present for items 1 – 5.1.3

NICE staff present

Meindert Boyson, Deputy Chief Executive & Director of CHTE Present for items 5.1.3 – 6.3.2

Henry Edwards, Associate Director Present for all items

Natalie Spray, Programme Director, Planning & Ops, TA & CCT Present for all items

Nick Lowe, Project Manager, DIT Present for all items

Harriet Wilson, Project Manager (Observing) Present for items 1 – 4.1.3

Caron Jones, Technical Adviser (Observing) Present for items 1 – 4.3.2

Rufaro Kausi, Technical Adviser Present for items 6 – 6.3.2

Carl Prescott, Technical Adviser Present for items 6 – 6.3.2

Luke Cowie, Technical Adviser Present for items 1 – 4.3.2

Neha Jiandani, Technical Adviser Present for items 1 – 4.1.3 & 6 – 6.3.2

Raphael Egbu, Technical Analyst (Observing) Present for items 6 – 6.3.2

Megan Dale, Technical Analyst (CEDAR) Present for items 6 – 6.3.2

Susan O’Connell, Technical Analyst (CEDAR) Present for items 6 – 6.3.2

Samuel Slayen, HTA Analyst (Observing) Present for items 6 – 6.3.2

Heather Stegenga, HTA Analyst Present for items 6 – 6.3.2

Philip Williams, Business Analyst, RIA Present for items 1 – 6.2.1

Neha Jiandani, Technical Adviser, Commercial Liaison Present for items 1 – 4.1.3 & 6 – 6.3.2

Ella Livingstone, Technical Adviser Commercial Risk Assessment Present for items 1 – 4.3.2 & 6 – 6.3.2

Emily Eaton Turner, Technical Analyst, Commercial Risk Assessment Present for items 1- 4.3.2 & 6 – 6.3.2

Helen Barrett, Senior Medical Editor Present for items 1 – 5.3.2

Korin Knight, Senior Medical Editor Present for Items 1 – 4.1.3

Olivia Havercroft, Senior Medical Editor Present for items 6 – 6.3.2

Catherine Pank, Assistant Project Manager, COT Present for items 1 – 5.1.3 & 6 – 6.3.2

Laura Marsden, Public Involvement Adviser, PIP Present for items 1 - 1 – 4.1.3 & 5 – 5.1.3

Lyn Davies, Coordinator, MIP Present for items 1 – 4.1.3 & 5 – 5.1.3

Rosalee Mason, Coordinator, MIP Present for items 1 – 4.1.3, 5 – 5.1.3 & 6 – 6.1.3

Gemma Smith, Coordinator, COT Present for all items

Laura Kelly, Administrator, COT Present for all items

Marcia Miller, Administrator, TA Present for all items

Rumana Zaman, Administrator, TA Present for all items

External assessment group representatives present

Nigel Fleeman, Liverpool Reviews, and Implementation Group (LRIG) Present for items 1 – 4.2.1

Rachel Houten, Liverpool Reviews, and Implementation Group (LRIG) Present for items 1 – 4.2.1

James Mahon, Liverpool Reviews, and Implementation Group (LRIG) Present for items 1 – 4.1.3

Tracey Jhita, BMJ Technology Assessment Group Present for items 5 – 5.2.1

Charlotta Klarner, BMJ Technology Assessment Group Present for items 5 – 5.2.1

Lena Al-Khudairy, Warwick Evidence Present for items 6 – 6.2.1

Ewen Cummins, Warwick Evidence Present for items 6 – 6.2.1

Clinical, Patient & NHS England experts present

Professor Peter Clark, Cancer Drug Fund Clinical Lead, NHS England Present for all items

Dr Ricky Frazer, Oncology Consultant, nominated by Merck Sharp & Dohme Present for items 1 – 4.1.3

Professor Thomas Powles, Professor of Genitourinary Oncology/Director of Barts Cancer Centre, Lead for Solid Tumour Research, nominated by Eisai & Merck Sharp & Dohme Present for items 1 – 4.1.3 & 5 – 5.1.3

Paula Brown, Patient Expert, nominated by Kidney Cancer UK Present for items 1 – 4.1.3

Sophie Ann Scott, Patient Expert, nominated by Kidney Cancer UK Present for items 1 – 4.1.3 & 5 – 5.1.3

Dr Natalie Charnley, Oncology Consultant, nominated by Kidney Cancer UK Present for items 5 – 5.1.3

Richard Jetten, Patient Expert, nominated by Kidney Cancer UK Present for items 5 – 5.1.3

## Minutes

### Introduction to the meeting

* 1. The chair welcomed members of the committee and other attendees present to the meeting.
	2. The chair noted apologies from Maria Brezitski, Mark Glover, and Mary Weatherstone.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Thursday 9 June 2022

### Appraisal of Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma [ID3760]

* 1. Part 1 – Open session
		1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Eisai Ltd and Merck Sharp & Dohme.
		2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Dr Ricky Frazer declared an indirect financial interest as he has been paid for speaking or advisory from Bristol-Myers Squibb Pharmaceuticals (nivolumab, ipilimumab) Eusa Pharma UK (tivozanib) Ipsen (cabozantinib) Novartis (pazopanib) & Pfizer (sunitinib) MSD (Pembrolizumab), Eisai (Lenvatinib) and Merck-Pfizer Alliance (Avelumab and Axitinib) It was agreed that this declaration would not prevent Dr Frazer from providing expert advice during this discussion.
* Professor Thomas Powles declared various indirect financial interests as he has have engaged in Advisory/Research Boards (Honorarium) for: AstraZeneca, BMS, Exelixis, Incyte, Ipsen, Merck, MSD, Novartis, Pfizer, Seattle Genetics, Merck Serono, Astellas, Johnson & Johnson, Eisai, Roche, and his institution has received grants from: AstraZeneca, BMS, Exelixis, Ipsen, Merck, MSD, Novartis, Pfizer, Seattle Genetics, Merck Serono, Astellas, Johnson & Johnson, Eisai, Roche. Professor Powles has received travel/Accommodation/Expenses from: Roche, Pfizer, MSD, AstraZeneca, Ipsen. It was agreed that these declarations would not prevent Professor Powles from providing expert advice during this discussion.
* Sophie Ann Scott declared an indirect financial interest as Kidney cancer UK has received funding within the last year from Merck, Sharp and Drome, Pfizer, and Bristol Myers Squibb. It was agreed this declaration would not prevent Sophie Ann Scott from providing expert advice during this discussion.
* Paula Brown declared an indirect financial interest as she worked for Sanofi Pasteur MSD for 11 years and left in 2008. The company was a 50/50 joint venture between Sanofi and MSD's vaccine division. Paula has no ongoing relationship with MSD and has never been directly employed by them. It was agreed that this declaration would not prevent Paula Brown from providing expert advice during this discussion.
* Prior to the meeting, Professor Nick Latimer declared a non-financial professional and personal interest, as he is member of the ScHARR team for a research project investigating methods for adjusting for treatment switching in clinical trials, funded by Merck, Sharpe and Dohme. This is not drug or appraisal specific and is about developing methods. Merck, Sharpe and Dohme are listed as a manufacturer. Professor Latimer also declared a direct financial interest, as in October 2021 he was paid to give Novartis staff a training session on survival analysis. This was not product or appraisal specific and was about methods (Novartis are listed as a comparator company.) It was agreed that these declarations would not prevent Professor Latimer from taking part in this discussion.
	+ 1. The Chair – Baljit Singh - led a discussion of the evidence presented to the committee. This information was presented to the committee by the lead team – Dr James Fotheringham (Clinical) Professor Nicholas Latimer (Cost) and Nigel Westwood (Lay).
	1. Part 2a – Closed session (members of the public, company representatives, and clinical and patient experts were asked to leave the meeting).
		1. The committee discussed confidential information submitted for this item.
	2. Part 2b – Closed session (external assessment group representatives were asked to leave the meeting)
		1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus..
		2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10629>

### Appraisal of Pembrolizumab for adjuvant treatment of renal cell carcinoma [ID3810]

* 1. Part 1 – Open session
		1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Merck Sharp & Dohme.
		2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Professor Nick Latimer declared a non-financial professional and personal interest, as he is member of the ScHARR team for a research project investigating methods for adjusting for treatment switching in clinical trials, funded by Merck, Sharpe and Dohme. This is not drug or appraisal specific and is about developing methods. Merck, Sharpe and Dohme are listed as a manufacturer.
* Dr Natalie Charnley declared various direct financial interests, as she has received meeting sponsorship from BMS, Ipsen and Eusa, and speaker fees from Pfizer and Ipsen, and research sponsorship from BMS. Dr Charnley also declared and indirect financial interest, as Kidney Cancer UK has received funding from BMS, Merck and Pfizer. It was agreed that these declarations would not prevent Dr Charney from providing expert advice in this discussion.
* Professor Thomas Powles declared a direct financial interest, as he has been renumeration by MSD for work on advisory boards. Professor Powles also declared a direct non-financial interest, due to receiving academic credit for satellite symposia, co-leading the pembrolizumab study and leading on a number of trials for MSD, and a indirect financial interest, having engaged in advisory/research Boards (Honorarium): AstraZeneca, BMS, Exelixis, Incyte, Ipsen, Merck, MSD, Novartis, Pfizer, Seattle Genetics, Merck Serono, Astellas, Johnson & Johnson, Eisai, Roche. Professor Powles has also received travel/Accommodation/Expenses from: Roche, Pfizer, MSD, AstraZeneca, Ipsen. It was agreed that these declarations would not prevent Professor Powles from providing expert advice during this discussion It was agreed that these declarations would not prevent Professor Powles from providing expert advice in this discussion.
* Sophie Ann Scott declared an indirect financial interest as Kidney cancer UK has received funding within the last year from Merck, Sharp and Drome, Pfizer, and Bristol Myers Squibb. It was agreed this declaration would not prevent Sophie Ann Scott from providing expert advice during this discussion.
	+ 1. The Chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by the Chair, Dr Charles Crawley.
	1. Part 2a – Closed session (company representatives, clinical and patient experts, and members of the public were asked to leave the meeting).
		1. The committee discussed confidential information submitted for this item.
	2. Part 2b – Closed session (external assessment group representatives were asked to leave the meeting).
		1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus..
		2. The committee asked the NICE technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10693>

### Appraisal of Olaparib for previously treated hormone-relapsed metastatic prostate cancer [ID1640]

* 1. Part 1 – Open session
		1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from AstraZeneca UK.
		2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* There were no interests declared for this appraisal.
	+ 1. The Chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by the Chair, Dr Charles Crawley.
	1. Part 2a – Closed session (company representatives and members of the public were asked to leave the meeting)
		1. The committee discussed confidential information submitted for this item.
	2. Part 2b – Closed session (external assessment group representatives were asked to leave the meeting).
		1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10584>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee B will be held on Wednesday 10 August 2022 and will start promptly at 09:30am.